Dexcom

Insulet’s Randomized Controlled Trial (OP5-003) Demonstrates Omnipod® 5 Automated Insulin Delivery System is Superior to Pump Therapy

Retrieved on: 
Friday, March 8, 2024

The OP5-003 Trial results were presented at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in Florence, Italy.

Key Points: 
  • The OP5-003 Trial results were presented at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in Florence, Italy.
  • "Omnipod 5 continues to demonstrate impressive clinical outcomes for people with type 1 diabetes,” said Professor Renard.
  • The control group (n=62) continued to use their usual insulin pump with a Dexcom G6 CGM, while the intervention group (n=132) used Omnipod 5 with Dexcom G6.
  • In conclusion, this multi-national, RCT data demonstrates the superiority of the Omnipod 5 AID System compared to standard pump therapy with CGM and indicates that it should be offered as a first-line therapy for adults with type 1 diabetes.

Dexcom Announces Upcoming Conference Presentation

Retrieved on: 
Tuesday, February 27, 2024

DexCom, Inc. (NASDAQ:DXCM) today announced that Sean Christensen, Vice President, Finance and Investor Relations, will present an update on the company at the 45th Annual Raymond James Institutional Investors Conference on Tuesday, March 5th.

Key Points: 
  • DexCom, Inc. (NASDAQ:DXCM) today announced that Sean Christensen, Vice President, Finance and Investor Relations, will present an update on the company at the 45th Annual Raymond James Institutional Investors Conference on Tuesday, March 5th.
  • The live presentation is scheduled to begin at approximately 8:40 AM EST and will be concurrently webcast.
  • Links to the webcast will be available on the Dexcom Investor Relations website at investors.dexcom.com and will be archived there for future reference.

Green Dot Appoints Michael Meston as Chief Human Resources Officer

Retrieved on: 
Monday, February 26, 2024

Green Dot Corporation (NYSE: GDOT), a leading digital bank and fintech powering consumers and businesses with seamless banking and payment solutions, today announced the appointment of Michael Meston as Chief Human Resources Officer.

Key Points: 
  • Green Dot Corporation (NYSE: GDOT), a leading digital bank and fintech powering consumers and businesses with seamless banking and payment solutions, today announced the appointment of Michael Meston as Chief Human Resources Officer.
  • “Michael is a proven human resources leader with the right experience in organizational change and talent development to help lead Green Dot as we build a workforce committed to seamlessly connecting more people and businesses to their money,” said George Gresham, Chief Executive Officer, Green Dot Corporation.
  • Prior to Bruker Corporation, Meston held senior human resources roles at Dexcom, Western Digital and Intel across the United States and Asia.
  • “Green Dot is enabling a generational shift in how consumers and businesses are accessing and utilizing financial services, and I am excited to contribute to that vision,” said Meston.

FDA Clears First Over-the-Counter Continuous Glucose Monitor

Retrieved on: 
Tuesday, March 5, 2024

SILVER SPRING, Md., March 5, 2024 /PRNewswire/ -- Today, the U.S. Food and Drug Administration cleared for marketing the first over-the-counter (OTC) continuous glucose monitor (CGM).

Key Points: 
  • SILVER SPRING, Md., March 5, 2024 /PRNewswire/ -- Today, the U.S. Food and Drug Administration cleared for marketing the first over-the-counter (OTC) continuous glucose monitor (CGM).
  • "CGMs can be a powerful tool to help monitor blood glucose.
  • The device presents blood glucose measurements and trends every 15 minutes in the accompanying app.
  • Data from a clinical study provided to the FDA showed that the device performed similarly to other iCGMs.

Edgepark adding first-of-its kind, fully automated insulin delivery system to diabetes portfolio

Retrieved on: 
Tuesday, February 13, 2024

TWINSBURG, Ohio, Feb. 13, 2024 /PRNewswire/ -- Edgepark announced today it is offering the newly launched Beta Bionics iLet Bionic Pancreas fully automated insulin delivery (AID) system as part of its comprehensive diabetes management solution portfolio. The iLet is the first and only system that does not require carbohydrate counting* and fully automates 100 percent of insulin doses. Designed for anyone six years of age and older living with Type 1 diabetes, it eliminates the traditional manual work previously involved with using an insulin pump.

Key Points: 
  • TWINSBURG, Ohio, Feb. 13, 2024 /PRNewswire/ -- Edgepark announced today it is offering the newly launched Beta Bionics iLet Bionic Pancreas fully automated insulin delivery (AID) system as part of its comprehensive diabetes management solution portfolio.
  • The iLet is the first and only system that does not require carbohydrate counting* and fully automates 100 percent of insulin doses.
  • "Edgepark is thrilled to offer the iLet as a first-of-its-kind device that uses automation to make diabetes simpler to navigate."
  • As with any insulin delivery system, users must also be able to load the insulin pump with insulin, insert an infusion set and troubleshoot when challenges occur.

Tandem Diabetes Care Launches Tandem Mobi, the World’s Smallest, Durable Automated Insulin Delivery System

Retrieved on: 
Tuesday, February 13, 2024

(NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced the United States commercial launch of its new Tandem Mobi, the world’s smallest, durable automated insulin delivery system for people living with diabetes.

Key Points: 
  • (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced the United States commercial launch of its new Tandem Mobi, the world’s smallest, durable automated insulin delivery system for people living with diabetes.
  • View the full release here: https://www.businesswire.com/news/home/20240213214991/en/
    Tandem Mobi, the world’s smallest, durable insulin delivery system, now shipping in the United States.
  • The Tandem Customer Care team is available now to help determine eligibility and potential timing of pump shipments for customers.
  • People living with diabetes interested in the Tandem Mobi system can start the order process at: www.tandemdiabetes.com/mobi .

Dexcom Reports Fourth Quarter and Fiscal Year 2023 Financial Results

Retrieved on: 
Thursday, February 8, 2024

DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2023.

Key Points: 
  • DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2023.
  • Fourth Quarter 2023 Financial Highlights:
    Revenue grew 27% versus the same quarter of the prior year to $1.03 billion on a reported basis and 26% on an organic1 basis.
  • Operating Income: GAAP operating income for the fourth quarter of 2023 was $216.9 million, compared to GAAP operating income of $125.4 million for the fourth quarter of 2022.
  • Non-GAAP operating income* for the fourth quarter of 2023 was $242.7 million, compared to non-GAAP operating income of $172.1 million for the fourth quarter of 2022.

Dexcom Launches Dexcom One+ Bringing Powerful, New Diabetes Management Technology to More People

Retrieved on: 
Tuesday, February 6, 2024

The system is available today in Spain, Belgium, and Poland and launches next week in the Netherlands.

Key Points: 
  • The system is available today in Spain, Belgium, and Poland and launches next week in the Netherlands.
  • In some countries Dexcom ONE+ replaces the previous generation Dexcom ONE sensor.
  • Dexcom also incorporated feedback from both end users and healthcare professionals when building Dexcom ONE+, ensuring an easy-to-use, highly effective, CGM experience for people treating their Type 1 or Type 2 diabetes with insulin.
  • Dexcom ONE+ is available today in Spain, Belgium and Poland, and will be available in the Netherlands next week.

Trinity Biotech Announces Acquisition of the CGM Assets of Waveform Technologies, Inc.

Retrieved on: 
Wednesday, January 31, 2024

DUBLIN, Ireland, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”) today announced it has entered into a definitive agreement to acquire the biosensor and Continuous Glucose Monitoring (“CGM”) assets of privately held Waveform Technologies, Inc. (“Waveform”) for $12.5 million in cash, 9 million American Depositary Shares (“ADSs”) of the Company and additional contingent consideration.

Key Points: 
  • Waveform will no longer sell the Cascade device and the Company will not sell that device in its current form.
  • The remaining $9.5 million is available for general corporate purposes including for the further development of the CGM and biosensor technologies.
  • Waveform is part of a portfolio company of Perceptive and the 9 million ADS being issued by the Company as partial consideration for the acquisition of the Waveform assets will be issued to Perceptive.
  • The Company will host a conference call on Wednesday, January 31 at 8:30 a.m. EST to discuss its recent Waveform acquisition.

Dexcom Schedules Fourth Quarter and Fiscal Year 2023 Earnings Release and Conference Call for February 8, 2024 at 4:30 p.m. Eastern Time

Retrieved on: 
Tuesday, January 23, 2024

DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its fourth quarter and fiscal year 2023 financial results after market close on Thursday, February 8, 2024.

Key Points: 
  • DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its fourth quarter and fiscal year 2023 financial results after market close on Thursday, February 8, 2024.
  • Management will hold a conference call to review the company's fourth quarter and fiscal year 2023 performance starting at 4:30 p.m. (Eastern Time) on the same day.
  • The conference call will be concurrently webcast.
  • The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will be archived there for future reference.